Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PDS Biotechnology Corporation - Common Stock (NQ:PDSB)

0.9376 +0.0025 (+0.27%)
Streaming Delayed Price Updated: 9:35 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PDS Biotechnology Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval
The company requested a meeting with the FDA to discuss an accelerated approval pathway for its lead cancer drug, PDS0101, following strong final data from its VERSATILE-002 trial. 
Via Stocktwits
Align Technology Stock Surges After-Hours On Teen Demand — Retail Sees Rally Ahead Into 2026
Q3 revenue of $995.7 million beat Align’s own forecast range of $965 million to $985 million, fueled by strong growth in clear aligners for teens and kids. 
Via Stocktwits
PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) Reports Narrower Q2 2025 Loss, Stock Rises on Clinical Progress
PDS Biotechnology (PDSB) reported Q2 2025 EPS of -$0.21, beating estimates. Stock rose 8.13% pre-market as clinical progress, including ASCO presentations, boosts investor optimism. No revenue yet. 
Via Chartmill
PDSB Loss Improves as Costs Drop
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Insights Ahead: PDS Biotechnology's Quarterly Earnings
 
Via Benzinga
A Look at PDS Biotechnology's Upcoming Earnings Report
 
Via Benzinga
Earnings Scheduled For August 13, 2025
 
Via Benzinga
Insights into PDS Biotechnology's Upcoming Earnings
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
PDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays Bearish
The company said the reduced losses were primarily due to decreased operating expenses. 
Via Stocktwits
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Uncovering Potential: PDS Biotechnology's Earnings Preview
 
Via Benzinga
Earnings Preview For PDS Biotechnology
 
Via Benzinga
Analyst Expectations for PDS Biotechnology's Future
 
Via Benzinga
Earnings Scheduled For May 14, 2025
 
Via Benzinga
PDS Biotechnology: Q3 Earnings Insights
 
Via Benzinga
Earnings Scheduled For March 27, 2025
 
Via Benzinga
Life Sciences Investor Forum Agenda Announced for March 13th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
A Preview Of PDS Biotechnology's Earnings
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q2 2024
PDSB stock results show that PDS Biotechnology beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q1 2024
PDSB stock results show that PDS Biotechnology beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q4 2023
PDSB stock results show that PDS Biotechnology beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
The Latest Analyst Ratings for PDS Biotechnology
 
Via Benzinga
Earnings Scheduled For November 14, 2024
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Earnings Scheduled For March 27, 2024
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million. 
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in March 2024
These 3 undervalued biotech stocks have been left behind so far but things could begin to turn around as we head into March. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.